Advanced in Lung Cancer

Sonja Loges

25 Martinistrasse Str, 
Hamburg, HH, DE 
Advanced in Lung Cancer
25 Martinistrasse Str, 
Hamburg, HH, DE 
OverviewLocationsClinical Research

Overview

Sonja Loges practices in Hamburg, Germany. Ms. Loges is rated as an Advanced expert by MediFind in the treatment of Lung Cancer. Her top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, Leukemia, and Bone Marrow Transplant.

Her clinical research consists of co-authoring 88 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 29 articles and participated in 1 clinical trial in the study of Lung Cancer.

Gender
Female

Locations

25 Martinistrasse Str, Hamburg, HH, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase Ib/II Multicenter Open-label Study of BGB324 as a Single Agent and in Combination With Cytarabine or Decitabine in Patients With Acute Myeloid Leukemia or as a Single Agent in Patients With Myelodysplastic Syndrome
A Phase Ib/II Multicenter Open-label Study of BGB324 as a Single Agent and in Combination With Cytarabine or Decitabine in Patients With Acute Myeloid Leukemia or as a Single Agent in Patients With Myelodysplastic Syndrome
Enrollment Status: Completed
Publish Date: December 19, 2024
Intervention Type: Drug
Study Drugs: Bemcentinib, Cytarabine, Decitabine
Study Phase: Phase 1/Phase 2
A Two-part, Open-label, Randomized, Phase 2/3 Study of Dinutuximab and Irinotecan Versus Irinotecan for Second Line Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer
A Two-part, Open-label, Randomized, Phase 2/3 Study of Dinutuximab and Irinotecan Versus Irinotecan for Second Line Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: December 09, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 2/Phase 3
View 1 Less Clinical Trial

88 Total Publications

Functional Characterization of Variants of Unknown Significance of Fibroblast Growth Factor Receptors 1-4 and Comparison With AI Model-Based Prediction.
Functional Characterization of Variants of Unknown Significance of Fibroblast Growth Factor Receptors 1-4 and Comparison With AI Model-Based Prediction.
Journal: JCO precision oncology
Published: June 17, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Loges's expertise for a condition
ConditionClose
      View All 13 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile